All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

In 2004, the International Committee of Medical Journals Editors (ICMJE) announced that randomized controlled trials (RCT) should be registered in a public trials registry before the recruitment of the first participant. This registration is now a condition for publication of the final trial results.\[[@pone.0173042.ref001]--[@pone.0173042.ref003]\]

Although trial registries have many benefits, some authors have suggested that they do not provide full and transparent information about RCT methodology.\[[@pone.0173042.ref004]--[@pone.0173042.ref006]\] Furthermore, a systematic review highlighted changes between the information in trial registries and the full RCT publication.\[[@pone.0173042.ref007]\] Publishing RCT protocols gives authors the opportunity to fully explain the rationale and proposed methods for their trial as well as related ethical and safety issues.\[[@pone.0173042.ref007], [@pone.0173042.ref008]\] Although publishing RCT protocols is not a common practice yet, it would potentially benefit trial users and complement the information in trial registries.\[[@pone.0173042.ref009], [@pone.0173042.ref010]\] Moreover, some experts have suggested that it should be mandatory to publish a protocol in order to minimise publication bias, false sample size reporting, switching of endpoints and increase transparency.

In recent years, several studies have addressed trends in the number and methodological quality of RCTs, \[[@pone.0173042.ref007], [@pone.0173042.ref011]--[@pone.0173042.ref013]\] and some addressed the discrepancies between RCTs and their initially published protocols.\[[@pone.0173042.ref014]--[@pone.0173042.ref016]\] However, no previous study has analysed trends in the publication of study protocols. Thus, little is known about trends in the practice of publishing trial protocols and their methodological quality. Since clinical medicine depends heavily on RCTs, transparency and high quality of RCT protocols is crucial. Therefore, the aim of this study was to assess worldwide trends in the volume and methodological quality of published protocols of RCTs through the first decade of the 21^st^ century.

Methods {#sec006}
=======

Aims {#sec007}
----

This study aimed to analyse trends in the publication of RCT protocols by assessing their volume and methodological quality across specialties and geographic regions.

Search strategy and selection process {#sec008}
-------------------------------------

PubMed and EMBASE were searched for trial protocols published in a ten-year period (1 September 2001 to 1 September 2011). In order to interpret the current status of methodological protocol quality, the time interval of ten years was chosen to minimize sampling error, and to ensure sustainability of the results. Also it provides an interesting insight in the development of methodological quality over time. The search syntax was as follows: (design rationale trial AND (randomised OR randomized)) OR (protocol trial AND (randomised or randomized)). All retrieved abstracts were screened according to the inclusion and exclusion criteria by two reviewers (KC, IA). If the relevance was uncertain, the full text of the article was obtained and reviewed. All disagreements were resolved through discussion and reaching consensus by including a third reviewer (MGB).\[[@pone.0173042.ref017]\] Protocols were included if they described a RCTs, defined as any prospective study assessing the effect of health care interventions in humans, randomly allocated to one of at least two study groups. Studies were excluded when (1) trial results were listed rather than protocols, (2) the study was not a RCT, (3) the study was not a study in humans, (4) the publication was not written in the English language, (5) no abstract was present, (6) no full text was present, and (7) the protocol was published after the study had been completed.

Study outcomes {#sec009}
--------------

The primary study outcome was methodological quality, with as secondary outcome the volume of published protocols. Methodological quality was assessed on two parameters:

1.  Individual methodological characteristics: All protocols were appraised according to a list adapted from the Cochrane risk of bias assessment tool and Chan and Altman's review including the following characteristics \[[@pone.0173042.ref011], [@pone.0173042.ref018]\]: Specification of primary outcome: adequate if primary outcome was explicitly specified in the protocol.Sample size calculation: adequate if performed and reported.Generation of allocation sequence: adequate if method of generation was reported and considered adequate (i.e. computer, random table, shuffle of cards).Concealment of treatment allocation: adequate if method of concealment was reported and considered adequate (i.e. envelopes, central unit for randomization, pharmacy, and independent statistician).Any blinding: adequate if any type of blinding was performed.Double blinding: adequate if both patient and one of the following were blinded: physician, observer, adjudication / consensus committee.Type of analysis: adequate if intention-to-treat analysis was explicitly mentioned.

2.  High vs. low quality designs: a trial was designated as 'high quality' if all three of the following methodological items were adequately reported: generation of allocation, concealment of allocation and intention-to-treat analysis. Blinding was not included as an item. Some have claimed that the role of blinding is overstated \[[@pone.0173042.ref019], [@pone.0173042.ref020]\]. Blinding may be impossible in some surgical trials.\[[@pone.0173042.ref021]--[@pone.0173042.ref024]\] Estimating correct implementation (or legitimate non-implementation) of blinding will not be possible, considering the great variety of possibilities to implement blinding among medical specialties. Therefore concealment of sequence generation was chosen instead, since it is a more generalizable parameter.\[[@pone.0173042.ref025]\]

Data extraction and definitions {#sec010}
-------------------------------

The following geographical, publishing and epidemiological characteristics were extracted: geographical region, specialty (based on the corresponding author and divided into the following (arbitrary) categories: Internal medicine and paediatrics, primary care, surgery (including subspecialties) and other), number of study centres, study arms (two arms, or three and more), number of randomized patients, trial design, funding (any kind of involvement of the industry was stated as commercial), presence of written informed consent, presence of a data safety monitoring board and plan for dealing with adverse events.

Data analysis {#sec011}
-------------

Characteristics and outcomes of included protocols were compared for three approximately equal periods: September 2001 to December 2004, January 2005 to May 2008 and June 2008 to September 2011.

Because of the search strategy used, only study protocols published in the last 4 months of the year 2001 and the first 8 months of the year 2011 were included. A random sample of publications from those years was added to the database as substitute for the missing months in 2001 and 2011. This was conducted according to the following manner: the number of publications per month of included protocols that were scored on quality in 2001 and 2011 respectively was calculated. This mean was multiplied by the number of missing months (8 in 2001 and 4 months in 2011 respectively). This resulted in 3 protocols being added to 2001 and 40 to 2011. The added protocols were randomly selected from period 1 and period 3, respectively.

Subgroup analyses were based on geographical region and medical specialty. The rational for examining geographical variation as well as medical specialties was that previous research demonstrated differences in methodological quality of surgical trials between continents.\[[@pone.0173042.ref026]\] Dichotomous outcomes were presented as the number (percentage) of events, whereas medians and interquartile ranges were used for continuous data. Study groups were compared by Fisher exact, χ2 and Mann-Whitney U tests, as appropriate. A *p*-value of \<0.05 was considered significant. The odds ratio (OR) with the corresponding 95% confidence intervals (95% CIs) was calculated for comparison of methodological quality between subgroups by means of univariate and multivariate logistic regression. All variables were included in the univariate analysis. Variables showing potential association (p\<0.2) in the univariate analysis were subsequently included in the multivariate analysis.\[[@pone.0173042.ref027]\] IBM SPSS Statistics for Windows Version 20.0 (IBM Corp., Armonk, NY, USA) was used for all statistical analysis.

Results {#sec012}
=======

Selection process {#sec013}
-----------------

Our search identified a total of 11 782 records. The selection process is depicted in figure A of the supporting information. The screening of the titles resulted in the selection of 6074 potentially relevant publications, and after screening by title and abstract, 615 publications remained. After final selection of full-text, 553 eligible protocols were identified. A random sample of 43 protocols was added to the database, resulting in a total of 596 protocols.

General characteristics and volume {#sec014}
----------------------------------

[Table 1](#pone.0173042.t001){ref-type="table"} shows the clinical and epidemiological characteristics of the included protocols.

10.1371/journal.pone.0173042.t001

###### Baseline and general characteristics of 596 published protocols of RCTs.

![](pone.0173042.t001){#pone.0173042.t001g}

  General characteristics             First period Sept 2001-Dec 2004   Second period Jan 2005-May 2008   Third period Jun 2008-Sept 2011   *p*-value
  ----------------------------------- --------------------------------- --------------------------------- --------------------------------- -----------
  Total                               69 (12)                           137 (23)                          390 (65)                          \<0.0001
  Region;                                                                                                                                   
  Europe                              24 (35)                           65 (47)                           190 (49)                          
  North America                       30 (44)                           46 (34)                           103 (26)                          
  Australasia                         11 (16)                           25 (18)                           86 (22)                           
  Other                               4 (6)                             1 (1)                             11 (3)                            0.02
  Specialty;                                                                                                                                
  Internal medicine and paediatrics   35 (51)                           75 (55)                           164 (42)                          
  Primary care                        23 (33)                           38 (28)                           115 (40)                          
  Surgery                             6 (9)                             19 (14)                           41 (11)                           
  Other                               5 (7)                             5 (4)                             30 (8)                            0.06
  Participating countries;                                                                                                                  
  Single country                      42 (61)                           94 (69)                           312 (80)                          
  Two or more countries               22 (32)                           31 (23)                           68 (17)                           
  Missing                             5 (7)                             12 (9)                            10 (3)                            0.006
  Participating centres;                                                                                                                    
  Single                              8 (12)                            28 (20)                           94 (24)                           
  Multi                               61 (88)                           109 (80)                          296 (76)                          0.06
  Funding;                                                                                                                                  
  Commercial                          33 (48)                           46 (34)                           113 (29)                          
  Non-commercial                      36 (52)                           91 (66)                           277 (71)                          0.008
  Trial design;                                                                                                                             
  Parallel                            56 (81)                           120 (88)                          325 (83)                          
  Other/Mixed                         13 (19)                           17 (12)                           65 (17)                           0.39
  Number of study arms reported;                                                                                                            
  Two arms                            43 (62)                           105 (77)                          299 (77)                          
  Three or more arms                  26 (38)                           32 (23)                           90 (23)                           0.032
  Number of randomized patients;      640                               358                               336                               
  Median (IQR)                        (308--2741)                       (197--852)                        (140--900)                        
  Written informed consent present;   41 (59)                           106 (77)                          287 (74)                          0.02
  Data safety Committee present;      37 (54)                           57 (42)                           139 (37)                          0.02
  Plan for adverse events present;    17 (25)                           50 (37)                           145 (37)                          0.13

Legend: This table describes all general characteristics of the included protocols, divided period by of publication. Study groups were compared by Fisher exact, χ2 and Mann-Whitney U tests, as appropriate. A *p*-value of \<0.05 was considered significant. IQR = inter quartile range.

The number of published protocols increased substantially over time, with 69, 137 and 390 published in the three periods, respectively (*p*\<0.0001) (figure A in the supporting information, and figure B of the supporting information). This constitutes a five-fold increase between the first and third period. In the first period, most published RCT protocols originated from North America, n = 30 (44%), while Europe was the most common in the second and third periods, n = 65 (47%) and n = 190 (48%), respectively.

'Internal medicine and paediatrics' was the most common specialty topic for RCTs of the four categories used, in all periods. Overall an increase in the absolute number of protocols was observed, although the numbers remained relatively low in the surgical category (n = 6, 19, 41). The proportion of non-industry-funded trials almost doubled between the first and last time period from 27 (39%) to 254 (65%), (*p*\<0.0001). There was a decrease in the reporting of the use of a data safety committee: from 54% in the first period to about 36% in the third period, (*p* = 0.02).

Methodological quality {#sec015}
----------------------

Methodological quality of the included protocols is presented in [Table 2](#pone.0173042.t002){ref-type="table"}.

10.1371/journal.pone.0173042.t002

###### Quality characteristics of published protocols.

![](pone.0173042.t002){#pone.0173042.t002g}

  Individual quality characteristics                              First period Sept 2001-Dec 2004 n = 69   Second period Jan 2005-May 2008 n = 137   Third period Jun 2008-Sept 2011 n = 390   *p*-value
  --------------------------------------------------------------- ---------------------------------------- ----------------------------------------- ----------------------------------------- -----------
  Primary outcome specified;                                      65 (94)                                  134 (98)                                  380 (97)                                  0.3
  Sample size calculation reported;                               64 (93)                                  123 (90)                                  359 (92)                                  0.7
  Adequate generation of allocation;                              30 (44)                                  79 (56)                                   260 (67)                                  0.001
  Concealment of allocation;                                      26 (38)                                  72 (53)                                   215 (55)                                  0.03
  Any Blinding;                                                   50 (73)                                  90 (66)                                   268 (69)                                  0.60
  Blinding---patient;                                                                                                                                                                          
  Yes                                                             27 (39)                                  50 (37)                                   103 (26)                                  
  No                                                              35 (51)                                  75 (55)                                   274 (70)                                  
  Unclear                                                         7 (10)                                   12 (9)                                    13 (3)                                    0.02
  Blinding---observer;                                                                                                                                                                         
  Yes                                                             33 (48)                                  67 (49)                                   235 (60)                                  
  No                                                              22 (32)                                  48 (35)                                   122 (31)                                  
  Unclear                                                         14 (20)                                  22 (16)                                   33 (9)                                    0.02
  Blinding---physician;                                                                                                                                                                        
  Yes                                                             25 (36)                                  37 (27)                                   76 (20)                                   
  No                                                              36 (52)                                  86 (63)                                   297 (76)                                  
  Unclear                                                         8 (12)                                   14 (10)                                   17 (4)                                    0.005
  Blinding---adjudication committee;                                                                                                                                                           
  Yes                                                             17 (25)                                  22 (16)                                   40 (10)                                   
  No                                                              52 (75)                                  114 (83)                                  350 (90)                                  
  Unclear                                                         0 (0)                                    1 (1)                                     0 (0)                                     0.003
  Double blinding;                                                27 (39)                                  49 (36)                                   97 (25)                                   0.008
  Prospective subgroup analyses;                                  16 (23)                                  37 (27)                                   80 (21)                                   0.3
  Intention to treat analyses;                                    43 (62)                                  97 (71)                                   293 (75)                                  0.08
  High quality protocols; [\*](#t002fn002){ref-type="table-fn"}   18 (26)                                  43 (31)                                   143 (37)                                  0.2

Legend: This table describes all characteristics concerning methodological quality, subdivided by period of publication. Study groups were compared by Fisher exact, χ2 and Mann-Whitney U tests, as appropriate. A *p*-value of \<0.05 was considered significant.

\* defined as presence of the following 3 criteria: adequate generation of allocation, concealment of allocation and intention-to-treat analysis.

The proportion of high quality protocols increased non-significantly across the study periods: 18 (26%), 43 (31%) and 143 (37%), (*p* = 0.17). Adequate methods for generation and concealment of allocation improved significantly over time (*p* = 0.03). Blinding was applied relatively frequent (about 70%) throughout the study periods, while the use of a blinded observer increased from 48% in the first period to 67 (60%) in the third (*p* = 0.02). The number of studies attempting to blind patients decreased significantly over time: from 39% and 37% in the first two periods, respectively, to 26% in the third (*p* = 0.02). The rate of double-blinding also decreased accordingly, from 39% and 36% to 25%, respectively (*p*\<0.008). There was a non-significant increase in explicit intention-to-treat analysis, from 62% in the first period to 75% in the third (*p* = 0.08).

Subgroup and regression analysis {#sec016}
--------------------------------

Subgroup analysis by geographic region is presented in [Table 3](#pone.0173042.t003){ref-type="table"}.

10.1371/journal.pone.0173042.t003

###### Subgroup analyses by region and speciality.

![](pone.0173042.t003){#pone.0173042.t003g}

  --------------------------------------------------------------- -------------------------------- ----------------------- --------------------- -----------
  Individual quality characteristics                              Europe n = 279                   North America n = 179   Australasia n = 122   *p*-value
  (number) (percentage)                                           \(n\) (%)                        \(n\) (%)               \(n\) (%)             
  Sample size calculation reported;                               253 (91)                         161 (90)                116 (95)              0.3
  Primary outcome specified;                                      274 (98)                         167 (93)                122 (100)             0.001
  Generation of allocation;                                       183 (66)                         94 (53)                 79 (65)               0.01
  Concealment of allocation;                                      154 (55)                         77 (43)                 72 (59)               0.009
  Some blinding;                                                  182 (65)                         125 (70)                88 (72)               0.3
  Blinding--patient;                                              71 (25)                          66 (37)                 34 (28)               0.03
  Blinding--observer;                                             165 (59)                         91 (51)                 72 (59)               0.2
  Blinding--physician;                                            47 (17)                          61 (34)                 22 (18)               \<0.0001
  Blinding--adjudication committee;                               20 (7)                           37 (21)                 17 (14)               \<0.0001
  Double blinding;                                                68 (24)                          65 (36)                 31 (25)               0.02
  Prospective subgroup analyses;                                  68 (24)                          40 (22)                 23 (19)               0.5
  Intention to treat analyses;                                    221 (79)                         108 (60)                93 (76)               \<0.0001
  High quality protocols; [\*](#t003fn002){ref-type="table-fn"}   99 (36)                          45 (25)                 53 (43)               0.003
  Individual quality characteristics                              Internal & paediatrics n = 274   Primary care n = 216    Surgery n = 66        *p*-value
  (number) (percentage)                                           \(n\) (%)                        \(n\) (%)               \(n\) (%)             
  Sample size calculation reported;                               256 (93)                         194 (90)                61 (92)               0.34
  Primary outcome specified;                                      271 (99)                         206 (95)                64 (97)               0.06
  Generation of allocation;                                       153 (56)                         140 (65)                48 (73)               0.02
  Concealment of allocation;                                      120 (44)                         127 (59)                38 (58)               0.002
  Some blinding;                                                  213 (78)                         129 (60)                33 (50)               \<0.0001
  Blinding--patient;                                              107 (39)                         35 (16)                 18 (27)               \<0.0001
  Blinding--observer;                                             156 (57)                         120 (56)                29 (44)               0.16
  Blinding--physician;                                            89 (33)                          24 (11)                 13 (20)               \<0.0001
  Blinding--adjudication committee;                               66 (24)                          7 (3)                   3 (5)                 \<0.0001
  Double blinding;                                                104 (38)                         33 (15)                 18 (27)               \<0.0001
  Prospective subgroup analyses;                                  68 (25)                          41 (19)                 14 (21)               0.30
  Intention to treat analyses;                                    194 (71)                         158 (73)                49 (74)               0.78
  High quality protocols; [\*](#t003fn002){ref-type="table-fn"}   77 (28)                          80 (37)                 29 (44)               0.02
  --------------------------------------------------------------- -------------------------------- ----------------------- --------------------- -----------

Legend: This table describes the subgroup analysis for methodological quality characteristics subdivided by specialty or region. Study groups were compared by Fisher exact, χ2 and Mann-Whitney U tests, as appropriate. A *p*-value of \<0.05 was considered significant.

\* Presence of the following three criteria: adequate generation of allocation, concealment of allocation and intention-to-treat analysis.

Adequate generation and concealment of allocation were equally frequent in RCT protocols from Europe and Australasia (around 60%), while less often so in protocols from North America (52% and 43%, respectively, *p*≤0.01). A similar trend was observed for adequate type of planned analyses (i.e. explicitly intention to treat): 79% and 76% for European and Australasian, respectively, compared to 60% for North American protocols (*p*\<0.0001). However, for blinding, North America achieved the highest percentages on practically all parameters. This is reflected in a double-blinding proportion of 36% compared to 24% and 25% for European and Australasian protocols, respectively (*p* = 0.02).

Subgroup analyses comparing the three most common specialties (Internal medicine and paediatrics, primary care and surgery) were performed ([Table 3](#pone.0173042.t003){ref-type="table"}). A significant difference in adequate generation of allocation and adequate concealment allocation was observed with the highest percentage achieved by surgery protocols (*p* = 0.02 and *p* = 0.002, respectively). On the other hand internal medicine and paediatrics consistently scored the highest percentage for blinding. The highest percentage of high quality protocols was in surgery (44%), (*p* = 0.018).

Univariate regression analysis shows origin from North America to be negatively associated with methodological quality, while origin from Europe, primary care or surgery as specialty, presence of informed consent and presence of a plan for adverse event were predictors for high methodological quality. In multi-variate analysis, all these factors were confirmed as independent predictors for methodological quality ([Table 4](#pone.0173042.t004){ref-type="table"}).

10.1371/journal.pone.0173042.t004

###### Regression analyses for high protocol quality.

![](pone.0173042.t004){#pone.0173042.t004g}

  --------------------------------------------------- ------- ------------------------------------ -----------
  Univariate regression analyses; Characteristics     \(n\)   Odds for high quality. OR (95% CI)   *p*-value
  Region;                                                                                          
  Europe                                              279     1                                    \-
  North America                                       179     0.61 (0.40--0.93)                    0.02
  Australasia                                         122     1.40 (0.91--2.20)                    0.13
  Specialty;                                                                                       
  Internal medicine and Paediatrics                   274     1                                    \-
  Primary care                                        216     1.51 (1.03--2.20)                    0.04
  Surgery                                             66      2.01 (1.15--3.47)                    0.01
  Number of participating countries; Single country   448     0.86 (0.57--1.31)                    0.5
  Participating centres; Single                       130     0.68 (0.44--1.04)                    0.08
  Funding; Commercial                                 192     1.14 (0.79--1.64)                    0.5
  Trial design; parallel                              501     1.15 (0.72--1.85)                    0.6
  Two study arms reported; Yes                        447     0.95 (0.64--1.41)                    0.8
  Written informed consent; Yes                       434     1.50 (1.01--2.23)                    0.04
  Data safety committee present; Yes                  233     1.18 (0.83--1.66)                    0.4
  Plan adverse events; Yes                            212     1.69 (1.19--2.40)                    0.003
  Multivariate regression analyses; Characteristics   \(n\)   Odds for high quality. OR (95% CI)   *p*-value
  Region;[\*](#t004fn002){ref-type="table-fn"}                                                     
  Europe                                              257     1                                    
  North America                                       168     0.63 (0.40--0.99)                    0.04
  Australasia                                         117     1.30 (0.82--2.06)                    0.3
  Specialty;                                                                                       
  Internal and paediatrics                            262     1                                    
  Primary care                                        214     1.57 (1.04--2.36)                    0.03
  Surgical specialties                                66      1.94 (1.09--3.45)                    0.02
  Written informed consent; Yes                       434     1.42 (0.90--2.23)                    0.13
  Plan adverse events; Yes                            212     1.81 (1.22--2.68)                    0.003
  --------------------------------------------------- ------- ------------------------------------ -----------

Legend: This table describes odds ratio (OR) with the corresponding 95% confidence intervals (95% CIs), and was calculated for comparison of methodological quality between subgroups by means of univariate and multivariate logistic regression. A *p*-value of \<0.05 was considered significant.

\*The small number of protocols from regions labelled as "other" (e.g. Africa and South America) were not included in the multivariate analysis, but are reported in [Table 1](#pone.0173042.t001){ref-type="table"}.

Discussion {#sec017}
==========

This first systematic empirical literature-based study on volume and quality of RCT protocols found a five-fold increase in the number of RCT protocols published over a ten-year period. Although the overall quality of published protocols improved, there were differences between continents, with protocols from Australasia and Europe being of higher quality than those from North America. This empirical literature-based study also found medical specialty to be correlated with the quality of published RCT protocols. Both primary care and surgical trials were associated with significantly higher quality compared to internal medicine and paediatric protocols. However, the confidence intervals of these parameters were relatively broad. Therefore it cannot be excluded that confounders that were not accounted for in the multivariate analysis contributed to the overall significance.

Previous studies have identified similar trends for the volume of published RCTs, as for published protocols.\[[@pone.0173042.ref026], [@pone.0173042.ref028]--[@pone.0173042.ref032]\] Whether protocol publication is increasing in popularity, or whether the augmentation in volume can be subscribed as a direct consequence of the increased amount of RCTs remains uncertain. In contrast with the current study, previous studies found published RCTs from Australasia to have the lowest rates of adequate reporting.\[[@pone.0173042.ref026], [@pone.0173042.ref033]--[@pone.0173042.ref036]\] The higher quality of surgical trials is remarkable especially since surgery used to have a reputation of being based on tradition rather than scientific research.\[[@pone.0173042.ref037], [@pone.0173042.ref038]\] A possible explanation for this phenomenon could be that due to the increasing rate of technological innovation more (e.g. minimally invasive) techniques have become available which allow for randomized comparisons. Moreover, increased awareness of the importance of surgical trials and enhanced training in trial methodology may have attributed to this improvement, but data are lacking. The recent IDEAL (Idea, Development, Exploration, Assessment, Long-term Follow-up) framework for surgical innovation may provide guidance for further improvement of trials on surgical interventions.\[[@pone.0173042.ref039], [@pone.0173042.ref040]\]

A troubling, and yet unexplained, finding is the apparent decrease in the use of a data safety committee from 54% in the first period to 36% in the third period. Close monitoring of this development is imperative.\[[@pone.0173042.ref041]\] In fact, the presence of a plan to handle adverse events seemed to be the strongest indicator for high quality RCT protocols. This might be explained by the importance of having such a plan is especially important in trials with a high degree of trial complexity; such trials will have been designed more carefully.\[[@pone.0173042.ref042]\] The intention of gaining written informed consent was also found to be a marker for high protocol quality. It seems that evidence-based guidance on how to design and perform RCTs would be welcomed. The Trial Forge platform and the SPIRIT guidelines (Standard Protocol Items: Recommendations for Interventional Trials) could be instrumental in this aspect as it strives to provide a systematic approach to improving trials and their protocols.\[[@pone.0173042.ref043], [@pone.0173042.ref044]\]

A shortcoming of our study is that the quality of the protocol does not automatically translate into the quality of the RCT. Although previous studies have compared the quality of RCTs with the quality of their protocols, such studies are scarce. Furthermore, they have used small samples and some of their results are contradictory.\[[@pone.0173042.ref009], [@pone.0173042.ref015], [@pone.0173042.ref045]\] Whether the trials described in the protocols in our study will be performed and published as designed, should be investigated further. This might reveal important insights in the life cycle of RCTs, and would allow prospective evaluation of factors that might be related to early termination of RCTs and non-publication. Another shortcoming of this study is that instead of the SPIRIT guidelines, the Cochrane risk of bias tool was used. The use of the SPIRIT item check list would have expanded the analysis. The drawback of the SPIRIT checklist, however, is that it covers over 50 items, including recommendations on version identifiers and statements regarding who obtained informed consent and who have access to the final data. These data are often not available in the published protocols. Therefore, a more selective approach was chosen in which a selected list of items was evaluated with empirical evidence showing their importance in that they affect final outcomes of RCTs. Additionally, the fact that these items have been used previously in several studies allows comparison between studies.

Medical specialties were subdivided into three fairly broad and subjective groups, in order to compare and contrast our findings across this range of subspecialties. This might have resulted in a loss of detail.\[[@pone.0173042.ref028], [@pone.0173042.ref029]\] Furthermore, only protocols published in English were included, which may have led to an underestimation of the number of published protocols, assuming that some are published in other languages. The inclusion of protocols was not limited to the top listed medical journals, which is a strength of this study. Also our review covers all medical specialties, which makes our study results generalizable.

In conclusion, this systematic review found a five-fold increase in the number of published study protocols in the past decade. The methodological quality of the protocols improved during the same period but varies greatly between regions and medical specialties, which suggests that different regions and medical specialties may face different challenges when seeking to improve the quality of RCTs. Nevertheless, it is important to strive for such improvements, given the importance of RCTs and systematic reviews of them as a source of reliable and robust evidence on the effects of healthcare interventions. Comprehensive training in RCT methodology, as for example is already offered in a master programme at the University of Oxford, amongst others, could benefit responsible conduct and reporting of RCTs greatly. The involvement of international medical societies in developing standards for training could enhance RCT quality improvement world-wide.
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###### 

**Figure A in:** Flow chart of systematic search strategy in PubMed and EMBASE. **Figure B in S1 File:** Volume of published protocols in number, per region; This figure describes the number of published protocols (listed on the x-axis) for different regions, sub divided in three time periods (listed on the y-axis).
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**Figure C in S2 File:** Filled in Prisma checklist.
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